Latest News

DEP® irinotecan phase 2 commences after positive phase 1 results

May 7th, 2020

Starpharma today announced successful completion of the phase 1 component of its phase 1 / 2 trial for DEP® irinotecan. The trial met its objective of evaluating safety, tolerability, pharmacokinetics and preliminary efficacy data, and identifying a recommended phase 2 dose. The trial will now transition seamlessly into phase 2, with recruitment activities underway at three sites. Two additional sites, The Beatson West of Scotland Cancer Centre (the Beatson) and the Kinghorn Cancer Centre in Sydney are also expected to commence recruitment shortly.

Read More

Starpharma presents at Macquarie Australia Conference

May 5th, 2020

Starpharma has been invited to present today at the Macquarie Australia Conference. Due to COVID-19, the Macquarie Australia Conference will be a virtual conference for registered institutional investors. The event will provide international and domestic institutions with the opportunity to hear from a range of invited Australian companies over three days. Starpharma is one of a handful of companies in the pharmaceutical/biotech and healthcare industries to be presenting during the conference.

Read More

SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)

Apr 15th, 2020

Starpharma today announced that its proprietary VivaGel® active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19 (coronavirus disease). SPL7013 inhibited the infection of cells with the SARS-CoV-2 virus and the finding was validated by replicate testing against a positive control compound, remdesivir (Gilead), which is considered a leading candidate for the treatment of COVID-19. The finding was also significant given that SPL7013 was reported to be the best performing test compound against SARS-CoV-2 in the laboratory’s assay to date. With these positive results, Starpharma is evaluating product concepts and formulation options for SPL7013, which may have potential applications in the prevention and management of COVID-19.



Read More

Quarterly Cashflow and Activity Report

Apr 7th, 2020

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2020.

Starpharma’s cash balance as at 31 March 2020 was $36.1 million, an increase of $0.2 million compared to the previous quarter’s cash balance. Net operating cash outflows for the quarter were $0.9 million, or $6.0 million for the nine months to 31 March 2020. Starpharma’s strong cash reserves and clean balance sheet places the Company in a strong position to continue to progress its commercial and R&D activities in the current uncertain global environment of the COVID-19 pandemic.

Read More

In the media

Small cap healthcare stocks surge to billion-dollar plays

Sep 30th, 2019

The Australian Financial Review mentioned that Starpharma was in a group of small cap biotech stocks in stage two trials that investors are closely in the next few years.

To read the full article, click here (paywall)

Read More

Starpharma’s VivaGel® BV regulatory approvals continue in Asia

Sep 3rd, 2019

Finance News Network reported Starpharma received further regulatory approval in another Asian country for its breakthrough product for bacterial vaginosis, VivaGel® BV. The news follows the first approval in the region announced on 15 August.

Read the full news coverage here.

Read More

Update on Starpharma’s latest positive interim DEP® trial results, VivaGel® and upcoming milestones

Aug 30th, 2019

Online news outlet Boardroom Media interviewed Starpharma CEO Dr Jackie Fairley following the release of its annual report and full-year results. In the interview, Dr Fairley shared the company’s latest DEP® trial results, as well as VivaGel® and upcoming milestones.

To listen to the full interview, click here.

Read More

Starpharma sees positive results in ovarian cancer treatment

Aug 29th, 2019

Online investor news outlet Finance News Network reported  Starpharma’s positive results for its novel HER-2 targeted DEP® conjugate (ADC) which outperformed the leading HER-2 ADC, Kadcyla®, in a human ovarian cancer model.

To watch the full news video, click here.

Read More

Shareholder Updates

Shareholder Update October 2017

Oct 18th, 2017

In this issue: 

>> DEP® docetaxel achieves positive phase 1 results and commences phase 2

 >> AZ presents first DEP® candidate AZD0466 – a Bcl2/xL inhibitor

>>  Successful VivaGel® BV phase 3 results

>> Update on other internal DEP® candidates

>> Grant awarded to Starpharma-Monash

>> Starpharma and Peter Mac Cancer Centre awarded grant

>> FY17 Financial results; >$60M cash at 30 June

>> Annual Report and Annual General Meeting

>> Starpharma News & Events


Download: Shareholder Update October 2017 (pdf file, 1.3mb)

Read More

Shareholder Update July 2017

Jul 4th, 2017

In this issue: 

>> Starpharma sells Agrochemicals business to Agrium for $35M cash

>> DEP®  irinotecan outperforms irinotecan in multiple cancer models

>> DEP®  docetaxel, DEP®  cabazitaxel and scale-up facilities

>> AstraZeneca pays US$2M DEP®  milestone to Starpharma

>> VivaGel®  BV phase 3 results timing and commercialisation

>> VivaGel®  condom launched in Canada

>> Sale of Ansell's Sexual Wellness division

>> Starpharma News & Events

Download: Shareholder Update July 2017 (pdf file, 710kb)

Read More

Sign up to receive news here